Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Apr;17(4):459–464. doi: 10.1111/j.1365-2125.1984.tb02372.x

A simple test for acetylator phenotype using caffeine.

D M Grant, B K Tang, W Kalow
PMCID: PMC1463406  PMID: 6721992

Abstract

A method is presented for the use of caffeine, in the forms commonly ingested by a large proportion of the world's population, to test for the clinically important acetylation polymorphism. Each of 146 subjects provided a spot sample of urine between 2 and 6 h after coffee, tea or cola soft drink consumption, and the molar ratio of 5-acetylamino-6- formylamino -3-methyluracil ( AFMU ) to 1-methylxanthine (1X) was determined by a simple h.p.l.c. assay. The ratio afforded segregation of three apparent modes of acetylation capacity in this population, in concordance with a standard sulphamethazine phenotyping procedure and with other methods using controlled caffeine intake and urine collections. The day-to-day consistency of the method was established in eight selected subjects.

Full text

PDF
462

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carr K., Oates J. A., Nies A. S., Woosley R. L. Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br J Clin Pharmacol. 1978 Nov;6(5):421–427. doi: 10.1111/j.1365-2125.1978.tb04606.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cartwright R. A., Glashan R. W., Rogers H. J., Ahmad R. A., Barham-Hall D., Higgins E., Kahn M. A. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet. 1982 Oct 16;2(8303):842–845. doi: 10.1016/s0140-6736(82)90810-8. [DOI] [PubMed] [Google Scholar]
  3. Chapron D. J., Blum M. R., Kramer P. A. Evidence for a trimodal pattern of acetylation of isoniazid in uremic subjects. J Pharm Sci. 1978 Jul;67(7):1018–1019. doi: 10.1002/jps.2600670740. [DOI] [PubMed] [Google Scholar]
  4. Chapron D. J., Kramer P. A., Mercik S. A. Kinetic discrimination of three sulfamethazine acetylation phenotypes. Clin Pharmacol Ther. 1980 Jan;27(1):104–113. doi: 10.1038/clpt.1980.16. [DOI] [PubMed] [Google Scholar]
  5. Drayer D. E., Reidenberg M. M. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther. 1977 Sep;22(3):251–258. doi: 10.1002/cpt1977223251. [DOI] [PubMed] [Google Scholar]
  6. EVANS D. A., MANLEY K. A., McKUSICK V. A. Genetic control of isoniazid metabolism in man. Br Med J. 1960 Aug 13;2(5197):485–491. doi: 10.1136/bmj.2.5197.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. EVANS D. A., WHITE T. A. HUMAN ACETYLATION POLYMORPHISM. J Lab Clin Med. 1964 Mar;63:394–403. [PubMed] [Google Scholar]
  8. Eidus L., Hodgkin M. M. Screening of isoniazid inactivators. Antimicrob Agents Chemother. 1973 Jan;3(1):130–133. doi: 10.1128/aac.3.1.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Evans D. A. An improved and simplified method of detecting the acetylator phenotype. J Med Genet. 1969 Dec;6(4):405–407. doi: 10.1136/jmg.6.4.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Grant D. M., Tang B. K., Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther. 1983 Mar;33(3):355–359. doi: 10.1038/clpt.1983.45. [DOI] [PubMed] [Google Scholar]
  11. Grant D. M., Tang B. K., Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther. 1983 May;33(5):591–602. doi: 10.1038/clpt.1983.80. [DOI] [PubMed] [Google Scholar]
  12. Lee E. J., Lee L. K. A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report. Br J Clin Pharmacol. 1982 Mar;13(3):375–378. doi: 10.1111/j.1365-2125.1982.tb01388.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schröder H. Simplified method for determining acetylator phenotype. Br Med J. 1972 Aug 26;3(5825):506–507. doi: 10.1136/bmj.3.5825.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tang B. K., Grant D. M., Kalow W. Isolation and identification of 5-acetylamino-6-formylamino-3-methyluracil as a major metabolite of caffeine in man. Drug Metab Dispos. 1983 May-Jun;11(3):218–220. [PubMed] [Google Scholar]
  15. Weber W. W., Brenner W. A filter paper method for determining isoniazid acetylator phenotype. Am J Hum Genet. 1974 Jul;26(4):467–473. [PMC free article] [PubMed] [Google Scholar]
  16. Wolf H., Lower G. M., Jr, Bryan G. T. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Scand J Urol Nephrol. 1980;14(2):161–165. doi: 10.3109/00365598009179555. [DOI] [PubMed] [Google Scholar]
  17. du Souich P., McLean A. J., Stoeckel K., Ohlendorf D., Gibaldi M. Screening methods using sulfamethazine for determining acetylator phenotype. Clin Pharmacol Ther. 1979 Dec;26(6):757–765. doi: 10.1002/cpt1979266757. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES